Protalix BioTherapeutics (PLX)
Protalix BioTherapeutics Beneish M-Score: -3.548
View PLX Beneish M-Score with YCharts Pro.
Access these YCharts Pro features:
Export any data you want
Save any chart as an image
Utilize advanced screener power
View 30 years of financial history
over 90 advanced calculations
Enjoy an advertising free experience
PLX Beneish M-Score Rankings
| Overall | 90th percentile | 346 of 3771 |
| Sector | 92nd percentile | 26 of 343 in Healthcare |
| Industry | 89th percentile | 6 of 58 in Biotechnology |
PLX Beneish M-Score Range, Past 5 Years
| Minimum | -3.548 | Dec 2011 |
| Maximum | -3.548 | Dec 2011 |
| Average | -3.548 |
About Beneish M Score
The Beneish M Score helps to uncover companies who are likely to be manipulating their reported earnings. Companies with a higher score are more likely to be manipulators. This is a probabilistic model, so it will not detect manipulators with 100% accuracy.
The best cut-off point depends on the costs mistakenly classifying in one of two ways:
1) Classifying firm that is manipulating earnings as a non-manipulator (Type I error), and
2) Classifying a firm as a manipulator when it actually was not manipulating (Type II Error).
Here are optimal cut-offs according to Beneish, presented as the score followed by the cost of Type I error relative to cost of Type II error):
M Score HTML Table:
| Score | Relative Error Costs (Type I:Type II) |
|---|---|
| M Score > -1.49 | (10:1) | M Score > -1.78 | (20:1) | M Score > -1.89 | (40+:1) |
Beneish excluded financial institutions from his sample when calculating the M-Score, so extreme care should be taken when looking at M-Scores of financial firms - their business models are different from the manufacturing and other service firms that Beneish used in his study.
If you want more details, here is the original Beneish M Score Paper, or you can learn about our calculation by clicking "Learn More" below.
Learn More
PLX News
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
May 29, 7:30AM GlobeNewswire
May 29, 7:30AM GlobeNewswire
@groberjg07 $ARNA $PLX immediately opened on FDA approval and yet we are still halted..
about 21 days ago by BiopharmaPro
about 21 days ago by BiopharmaPro
$PLX http://stks.co/3lrN recovery after the Approval profit taking, will be volatile till the option expiry 5/19
about 21 days ago by gantosj
about 21 days ago by gantosj
Protalix BioTherapeutics to Present at Three Upcoming Healthcare Conferences
May 10, 7:30AM GlobeNewswire
May 10, 7:30AM GlobeNewswire
$PLX pumper article won't save this thing. massive insider selling tells the story. this wont go above 7.5 imo
about 23 days ago by johnkelly
about 23 days ago by johnkelly
well apparantly $PLX insiders dont think it'll go over $7.50 anytime soon! never seen so much selling lol http://stks.co/3iSq
about 24 days ago by johnkelly
about 24 days ago by johnkelly
$VTUS Phase 3 data for anal fissures, expected by May 15th, 120M market share, no competitor, grossly undervalued $JAZZ $PLX $VVUS $$
about 25 days ago by peterumble
about 25 days ago by peterumble
RT @peterumble Short stocks: $EXEL $RGEN $PLX $POZN $CVM , markets hate uncertainty $SPY- SPY down 3.1% POZN up 0.8% since Wed. close. DD.
about 27 days ago by Glopolon
about 27 days ago by Glopolon
$PLX glad i held on..this is going LOW on monday. ceo has NO shares now..dont blame them, i would have done the same
about 27 days ago by gotgame83
about 27 days ago by gotgame83
$PLX why do people think the pfe is going to buy them out? dont they already have a partnership with them? any benefit for pfe?
about 27 days ago by gotgame83
about 27 days ago by gotgame83
$PLX last minute buying ahed of "weekend buyout" comical...
about 27 days ago by johnkelly
about 27 days ago by johnkelly
Canaccord Genuity Reiterates a 'Buy' on Protalix BioTherapeutics (PLX); U.S. Tali Approval May Unlock Potential
Apr 19, 9:14AM Street Insider
Apr 19, 9:14AM Street Insider
Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Mar 16, 4:01PM GlobeNewswire
Mar 16, 4:01PM GlobeNewswire
Auriga Reiterate a 'Buy' on Protalix BioTherapeutics (PLX); No Material Changes in 10-K
Mar 01, 10:42AM Street Insider
Mar 01, 10:42AM Street Insider
Protalix BioTherapeutics to Participate at Two Upcoming Global Healthcare Conferences
Feb 23, 7:30AM GlobeNewswire
Feb 23, 7:30AM GlobeNewswire
Protalix BioTherapeutics Announces Closing of Public Offering and Exercise of Over-Allotment Option
Feb 22, 4:15PM GlobeNewswire
Feb 22, 4:15PM GlobeNewswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| PLX | 6.42 | +0.07 | +1.10% | 576.71M |
| PLUS | 31.43 | -0.27 | -0.85% | 255.50M |
| PLUG | 1.17 | +0.02 | +1.62% | 43.49M |
| PLT | 30.08 | -0.46 | -1.51% | 1.313B |
| PLPC | 54.81 | -1.51 | -2.68% | 292.14M |
| PLOW | 12.78 | -0.12 | -0.93% | 285.48M |
| PLNR | 1.85 | +0.05 | +2.78% | 36.67M |
| PLM | 0.7177 | -0.02 | -3.01% | 130.13M |
| PLL | 55.65 | -0.76 | -1.35% | 6.510B |
| PHX | 25.49 | +0.07 | +0.28% | 209.97M |
